| Item Type | Name |
|
Concept
|
Liver Cirrhosis, Alcoholic
|
|
Concept
|
Liver Cirrhosis
|
|
Concept
|
Liver Cirrhosis, Biliary
|
|
Academic Article
|
Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events.
|
|
Academic Article
|
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
|
|
Academic Article
|
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
|
|
Academic Article
|
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
|
|
Academic Article
|
Non-alcoholic fatty liver disease.
|
|
Academic Article
|
Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD.
|
|
Academic Article
|
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.
|
|
Academic Article
|
Medical and Obstetric Complications Among Pregnant Women With Liver Cirrhosis.
|
|
Academic Article
|
Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?
|
|
Academic Article
|
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.
|
|
Academic Article
|
Fundal variceal bleeding after correction of portal hypertension in patients with cirrhosis.
|
|
Academic Article
|
Thanks to CLD for Small Favors: Reduced CVD Risk in Patients Awaiting Liver Transplantation.
|
|
Academic Article
|
STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus.
|
|
Academic Article
|
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.
|
|
Academic Article
|
The times they are a-changin' (for NAFLD as well).
|
|
Academic Article
|
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum.
|
|
Academic Article
|
Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges.
|
|
Academic Article
|
Real-World Burden of Nonalcoholic Steatohepatitis.
|
|
Academic Article
|
Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.
|
|
Academic Article
|
Nonalcoholic fatty liver disease.
|
|
Academic Article
|
Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.
|
|
Academic Article
|
Editorial: sarcopenia in liver transplantation-our weakest patients may need the strongest push.
|
|
Academic Article
|
Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock?
|
|
Academic Article
|
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial.
|
|
Academic Article
|
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
|
|
Academic Article
|
Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium.
|
|
Academic Article
|
Fatty Liver Disease: Diagnosis and Stratification.
|
|
Academic Article
|
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
|
|
Academic Article
|
Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey.
|
|
Academic Article
|
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
|
|
Academic Article
|
Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Nonhepatocellular Cancers.
|
|
Academic Article
|
Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
|
|
Academic Article
|
Natural history of NASH cirrhosis in liver transplant waitlist registrants.
|
|
Academic Article
|
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.
|
|
Academic Article
|
Implementation of a liver health check in people with type 2 diabetes.
|
|
Academic Article
|
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
|
|
Academic Article
|
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
|